Topic: Integrated Precision Strategies for Cardiac Injury and Heart Failure: From Early Detection to Innovative Therapy

Heart failure (HF) remains a global health challenge, representing the common end-stage of various cardiac injuries. In the context of global population aging, the intersection of biological senescence and pathological remodeling significantly complicates disease progression. Traditional "one-size-fits-all" approaches are increasingly being replaced by precision medicine, which aims to tailor prevention and treatment to an individual’s genetic, molecular, and clinical profile.

This Special Topic aims to bridge the gap between basic mechanistic discoveries and clinical applications. We seek to explore integrated strategies to identify subclinical cardiac injury via advanced biomarkers and artificial intelligence (AI)-driven diagnostics to implement cutting-edge therapies such as gene editing and regenerative medicine. Areas of Interest Include (but are not limited to):

1. Precision Prognosis & Risk Modeling (Clinical Research)

● Multi-modal Risk Scoring: Integration of clinical phenotyping, advanced imaging (CMR, strain imaging), and multi-omics (proteomics, metabolomics) to predict HF progression.

● AI-Driven Predictive Analytics: Leveraging machine learning and deep learning to identify high-risk sub-phenotypes, assess biological aging and frailty, characterize age-related vulnerability and remodeling following cardiac injury, and construct "digital twins" in aging populations.

● Dynamic Monitoring: Research on digital health tools, wearable biosensors, and frailty indices for real-time monitoring and long-term prognosis.

● Real-World Evidence: Comparative effectiveness research evaluating the impact of precision-guided interventions on mortality and rehospitalization.

● Clinical Cohort-Based Prognosis evaluation, prognostic risk stratification and standardized risk prediction model development.

2. Early Detection & Mechanistic Insights (Translational Research)

● Novel Biomarkers: Identification of early indicators for subclinical cardiac injury, including epigenetic clocks and telomere dynamics.

● Pathological Remodeling: The role of cellular senescence, inflammation and metabolic reprogramming in cardiac injury and repair.

● Genetic Drivers: Epigenetic and genetic regulators of heart failure progression in the elderly.

3. Innovative Therapies (Basic & Clinical Research)

● Next-Generation Pharmacotherapy: Precision application of SGLT2 inhibitors, GLP-1 receptor agonists, targeted small molecules and other agents.

● Breakthrough Interventions: Advances in gene editing (CRISPR-Cas9), cardiac regeneration, and tissue engineering.

● Device-Based Interventions: Minimally invasive structural heart therapies and personalized device management.

Aging; precision prognosis, AI, risk modeling, early detection, novel biomarkers, gene editing, epigenetics, small molecules, pharmacotherapy, device-based interventions